A Win For Ocugen, Inc.

Ocugen, Inc. (OCGN:NASDAQ) shot up at $15.81, a gain of 201.1%. On Fri 05 Feb 21, OCGN:NASDAQ hit a New 2-Week High of $5.25. The stock got featured on our News Catalysts scanner on Mon 08 Feb 21 at 03:52 PM in the 'INVESTOR UPDATE' category. From Fri 22 Jan 21, the stock recorded 50.00% Up Days and 36.36% Green Days

About Ocugen, Inc. (OCGN:NASDAQ)

Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).